| 词条 | Grindeks |
| 释义 |
| name =AS Grindeks | logo = Grindeks.gif | type = Public | traded_as = {{OMX|RIS24415|GRD1R}} | genre = | fate = | predecessor = | successor = | foundation = 11 October 1991[1] | founder = | defunct = | location_city = Riga | location_country = Latvia | location = | locations = | area_served = Worldwide | key_people = Kirovs Lipmans (Chairman)[2] Juris Bundulis (CEO) Janis Romanovskis (Chief Finance and Administrative Officer) | industry = Pharmaceuticals | products = | services = | revenue = € 132,4 million (2017)[3] | operating_income = | net_income = {{profit}} € 10.3 million (2017)[3] | aum = | assets = | equity = | owner = Kirovs Lipmans (33.29%))[4] Anna Lipmane (16.65%)[5] | num_employees = 1355 (2017)[6] | parent = | divisions = | subsid = | homepage = grindeks.lv | footnotes = | intl = }}AS Grindeks (branded as Grindex), is a Latvian company listed on the Nasdaq Riga with production of pharmaceutical drugs, medicine and phytochemical medicine. The company was founded 17 October 1991 and is a joint stock company since 25 August 1997.[1] One of the key drugs for Grindeks is meldonium, marketed under the trade name Mildronate.[7][8][9] Meldonium is used for the treatment of angina and myocardial infarction by inhibiting the carnitine biosynthesis pathway via the inhibition of gamma-butyrobetaine dioxygenase.[10][11][12][13][14] In 2017, Grindeks had a turnover revenue of €132.4 million with a profit of €10.3 million.[3] Grindeks had 1355 employees[6] and the main shareholders were Kirovs Lipmans (33.29%) and Anna Lipmane (16.65%)[2] {{-}}References{{commons category|AS Grindeks}}1. ^1 {{cite web |url=http://www.nasdaqbaltic.com/upload/reports/grd/2015_ar_en_eur_con_ias.pdf|title=Joint Stock Company "Grindeks" Annual Report 2015 |publisher=nasdacomxbaltic.com |page=3 |date=2010-04-27 |accessdate=2010-11-01}} 2. ^1 {{cite web |url=http://www.nasdaqbaltic.com/upload/reports/grd/2015_ar_en_eur_con_ias.pdf |title=Joint Stock Company "Grindeks" Annual Report 2015 |publisher=nasdacomxbaltic.com |page=5 |accessdate=2016-11-01}} 3. ^1 2 {{cite web |url=http://www.nasdaqbaltic.com/upload/reports/grd/2015_ar_en_eur_con_ias.pdf |title=Joint Stock Company "Grindeks" Annual Report 2015 |publisher=nasdacomxbaltic.com |page=7|accessdate=2016-11-01}} 4. ^{{cite web |url=http://www.nasdaqbaltic.com/upload/reports/grd/2015_ar_en_eur_con_ias.pdf |title=Joint Stock Company "Grindeks" Annual Report 2015 |publisher=nasdacomxbaltic.com |page=5 |accessdate=2016-11-01}} 5. ^{{cite web |url=http://www.nasdaqbaltic.com/upload/reports/grd/2015_ar_en_eur_con_ias.pdf |title=Joint Stock Company "Grindeks" Annual Report 2015 |publisher=nasdacomxbaltic.com |page=5 |accessdate=2016-11-01}} 6. ^1 {{cite web |url=http://www.nasdaqbaltic.com/upload/reports/grd/2015_ar_en_eur_con_ias.pdf |title=Joint Stock Company "Grindeks" Annual Report 2015 |publisher=nasdacomxbaltic.com |page=34 |accessdate=2010-11-01}} 7. ^Biotech Intelligence. http://www.biotech-intelligence.com/html/html/pool_7/91cc83b0e3f8b4edbbda2a42ae43e1b1.html (accessed 17 May 2012). 8. ^PMR. Pharmaceutical, Healthcare and Medical Sector in Central and Eastern Europe: Industry News, Analyses and Market Data. {{cite web |url=http://www.ceepharma.com/63359/Grindex-names-Russian-manufacturing-partner-for-Mildronate.shtml |title=Archived copy |accessdate=2012-06-13 |deadurl=yes |archiveurl=https://archive.is/20120728194513/http://www.ceepharma.com/63359/Grindex-names-Russian-manufacturing-partner-for-Mildronate.shtml |archivedate=28 July 2012 |df=dmy-all }} (accessed 17 May 2012). 9. ^Evaluate Pharma. {{cite web |url=https://www.evaluatepharma.com/Universal/View.aspx?type=Story&id=137196 |title=Archived copy |accessdate=2012-06-13 |deadurl=yes |archiveurl=https://archive.is/20121217133224/http://www.evaluatepharma.com/Universal/View.aspx?type=Story&id=137196 |archivedate=17 December 2012 |df=dmy-all }} (accessed 17 May 2012). 10. ^{{cite journal |vauthors=Sesti C, Simkhovich BZ, Kalvinsh I, Kloner RA | title = Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics | journal = J. Cardiovasc. Pharmacol. | volume = 47 | issue = 3 | pages = 493–9 |date=March 2006 | pmid = 16633095 | doi = 10.1097/01.fjc.0000211732.76668.d2 }} 11. ^{{cite journal |vauthors=Liepinsh E, Vilskersts R, Loca D, Kirjanova O, Pugovichs O, Kalvinsh I, Dambrova M | title = Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction | journal = J. Cardiovasc. Pharmacol. | volume = 48 | issue = 6 | pages = 314–9 |date=December 2006 | pmid = 17204911 | doi = 10.1097/01.fjc.0000250077.07702.23 }} 12. ^{{cite journal |vauthors=Hayashi Y, Kirimoto T, Asaka N, Nakano M, Tajima K, Miyake H, Matsuura N | title = Beneficial effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction | journal = Eur. J. Pharmacol. | volume = 395 | issue = 3 | pages = 217–24 |date=May 2000 | pmid = 10812052 | doi = 10.1016/S0014-2999(00)00098-4 }} 13. ^{{cite journal |vauthors=Leung IK, Krojer TJ, Kochan GT, Henry L, von Delft F, Claridge TD, Oppermann U, McDonough MA, Schofield CJ | title = Structural and mechanistic studies on γ-butyrobetaine hydroxylase | journal = Chem. Biol. | volume = 17 | issue = 12 | pages = 1316–24 |date=December 2010 | pmid = 21168767 | doi = 10.1016/j.chembiol.2010.09.016 }} 14. ^{{cite journal |vauthors=Tars K, Rumnieks J, Zeltins A, Kazaks A, Kotelovica S, Leonciks A, Sharipo J, Viksna A, Kuka J, Liepinsh E, Dambrova M | title = Crystal structure of human gamma-butyrobetaine hydroxylase | journal = Biochem. Biophys. Res. Commun. | volume = 398 | issue = 4 | pages = 634–9 |date=August 2010 | pmid = 20599753 | doi = 10.1016/j.bbrc.2010.06.121 }} External links
5 : Pharmaceutical companies of Latvia|Companies based in Riga|Pharmaceutical companies established in 1991|Latvian brands|1991 establishments in Latvia |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。